Skip to main content
2022 Guide to Patient Support Services

Regeneron & Sanofi Genzyme

2022 Oncology Guide to Patient Support Services

Regeneron and Sanofi Genzyme Libtayo Surround Program


Regeneron and Sanofi Genzyme offer the Libtayo Surround program to assist patients while taking Libtayo (Table).

Libtayo Surround Program

This program offers an array of patient support services to help patients throughout their treatment journey, including a Commercial Copay Program, Patient Assistance Program, dedicated Patient Navigators, and a Patient Starter Kit.

Commercial Copay Program

Eligible patients with commercial insurance may pay as little as $0 for Libtayo, which includes any product-specific copay, coinsurance, and insurance deductibles, with a cap of $25,000 annually. Patients may be eligible if they:

  • Are 18 years of age or older
  • Are a resident of the United States or its territories
  • Have been prescribed Libtayo for an FDA-approved indication
  • Have commercial insurance
  • Do not participate in Medicare, Medicaid, Veterans Affairs/Department of Defense, TRICARE, or similar federal or state programs.

Patient Assistance Program

The Libtayo Surround Patient Assistance Program provides access to Libtayo at no cost to eligible patients who are uninsured or underinsured. Libtayo Surround can help evaluate patients’ eligibility for this program.

Patient Navigators

Once enrolled in Libtayo Surround, patients have access to dedicated Patient Navigators who will answer any questions about resources and support, send reminders about upcoming appointments, send patients a Patient Starter Kit to provide helpful materials for starting treatment with Libtayo, and send e-mails and direct mail to help educate patients and caregivers about their condition and treatment.

Click here to learn more or to enroll your patient in the Libtayo Surround program, or call 877-542-8296.

TABLE Regeneron/Sanofi Genzyme Oncology Drug

Patient support programs

Libtayo (cemiplimab-rwlc) injection
Treatment of metastatic cutaneous squamous-cell carcinoma (CSCC) or locally advanced CSCC in patients who are not candidates for curative surgery or radiation; treatment of patients with locally advanced or metastatic basal-cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate; first-line treatment of patients with non–small-cell lung cancer whose tumors have high PD-L1 expression as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is either metastatic or locally advanced where patients are not candidates for surgical resection or definitive chemoradiation
Patient support program

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"